Cargando…

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer

BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve cancer-related outcomes in patients with BC. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Aft, R L, Naughton, M, Trinkaus, K, Weilbaecher, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389411/
https://www.ncbi.nlm.nih.gov/pubmed/22617128
http://dx.doi.org/10.1038/bjc.2012.210
_version_ 1782237307158396928
author Aft, R L
Naughton, M
Trinkaus, K
Weilbaecher, K
author_facet Aft, R L
Naughton, M
Trinkaus, K
Weilbaecher, K
author_sort Aft, R L
collection PubMed
description BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve cancer-related outcomes in patients with BC. METHODS: Disease-free survival (DFS; secondary end point) and overall survival (OS; tertiary end point) were evaluated in 119 women with stage II/III BC randomised to intravenous ZOL 4 mg every 3 weeks for 1 year or no ZOL (control) starting with the first chemotherapy cycle. RESULTS: At 61.9 months’ median follow-up, there was no significant difference in recurrence or survival between study arms. However, time to recurrence or death (DFS) was significantly different between subgroups defined by oestrogen receptor (ER) status (interaction P=0.010 for DFS and 0.025 for OS). Hazard ratios (HRs) for disease recurrence and death were significantly less among patients with ER-negative (ER(−)) tumours who received ZOL vs no ZOL (DFS: HR=0.361, 95% confidence interval (CI) 0.148, 0.880; OS: HR=0.375, 95% CI 0.143, 0.985). CONCLUSION: ZOL administered with chemotherapy may improve DFS and OS in a subset of BC patients with ER(−) tumours. This study was not powered to compare subgroups of patients; thus, these findings should be considered hypothesis generating.
format Online
Article
Text
id pubmed-3389411
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33894112012-07-05 Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer Aft, R L Naughton, M Trinkaus, K Weilbaecher, K Br J Cancer Clinical Study BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve cancer-related outcomes in patients with BC. METHODS: Disease-free survival (DFS; secondary end point) and overall survival (OS; tertiary end point) were evaluated in 119 women with stage II/III BC randomised to intravenous ZOL 4 mg every 3 weeks for 1 year or no ZOL (control) starting with the first chemotherapy cycle. RESULTS: At 61.9 months’ median follow-up, there was no significant difference in recurrence or survival between study arms. However, time to recurrence or death (DFS) was significantly different between subgroups defined by oestrogen receptor (ER) status (interaction P=0.010 for DFS and 0.025 for OS). Hazard ratios (HRs) for disease recurrence and death were significantly less among patients with ER-negative (ER(−)) tumours who received ZOL vs no ZOL (DFS: HR=0.361, 95% confidence interval (CI) 0.148, 0.880; OS: HR=0.375, 95% CI 0.143, 0.985). CONCLUSION: ZOL administered with chemotherapy may improve DFS and OS in a subset of BC patients with ER(−) tumours. This study was not powered to compare subgroups of patients; thus, these findings should be considered hypothesis generating. Nature Publishing Group 2012-06-26 2012-05-22 /pmc/articles/PMC3389411/ /pubmed/22617128 http://dx.doi.org/10.1038/bjc.2012.210 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Aft, R L
Naughton, M
Trinkaus, K
Weilbaecher, K
Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title_full Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title_fullStr Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title_full_unstemmed Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title_short Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
title_sort effect of (neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage ii/iii breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389411/
https://www.ncbi.nlm.nih.gov/pubmed/22617128
http://dx.doi.org/10.1038/bjc.2012.210
work_keys_str_mv AT aftrl effectofneoadjuvantzoledronicacidondiseasefreeandoverallsurvivalinclinicalstageiiiiibreastcancer
AT naughtonm effectofneoadjuvantzoledronicacidondiseasefreeandoverallsurvivalinclinicalstageiiiiibreastcancer
AT trinkausk effectofneoadjuvantzoledronicacidondiseasefreeandoverallsurvivalinclinicalstageiiiiibreastcancer
AT weilbaecherk effectofneoadjuvantzoledronicacidondiseasefreeandoverallsurvivalinclinicalstageiiiiibreastcancer